.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Argus Health
AstraZeneca
Deloitte
Chubb
Accenture
Federal Trade Commission
Julphar
US Department of Justice
Dow

Generated: June 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,208,256

« Back to Dashboard

Claims for Patent: 5,208,256

Title: Treatment of ocular hypertension with a synergistic combination for ocular administration
Abstract:A method for treatment of ocular hypertension which comprises ocularly administering, to a subject in need of such treatment, an oculo-hypotensively synergistic combination of (a) a 13,14-dihydro-15-keto-20-loweralkylprostaglandin or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof, and (b) a polyoxyethylenesorbitan unsaturated higher aliphatic acid monoester in an amount effective in treatment of ocular hypertension.
Inventor(s): Ueno; Ryuji (Hyogo, JP)
Assignee: R-Tech Ueno, Ltd. (Osaka, JP)
Application Number:07/703,660
Patent Claims: 1. A method for treatment of ocular hypertension which comprises ocularly administering, to a subject in need of such treatment, an oculo-hypotensively synergistic combination of

(a) a 13,14-dihydro-15-keto-20-loweralkylprostaglandin or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof, and

(b) a polyoxyethylenesorbitan unsaturated higher aliphatic acid monoester in an amount effective in treatment of ocular hypertension.

2. The method according to claim 1, in which the component (a) is a 13,14-dihydro-15-keto-20-loweralkylprostaglandin A, B, C, D, E or F, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof.

3. The method according to claim 1, in which the component (a) is a 13,14-dihydro-15-keto-20-ethylprostaglandin A, B, C, D, E or F, or a pharmaceutically acceptable salt thereof, or a lower alkyl ester thereof.

4. The method according to claim 1, in which the component (a) is a 13,14-dihydro-15-keto-20-loweralkylprostaglandin F.sub.2 .alpha. or a pharmaceutically acceptable salt thereof, or a lower alkyl ester thereof.

5. The method according to claim 1, in which the component (a) is a 13,14-dihydro-15-keto-20-ethylprostaglandin F.sub.2 .alpha., or a pharmaceutically acceptable salt thereof, or a lower alkyl ester thereof.

6. The method according to claim 1, in which the component (b) is polyoxyethylenesorbitan monooleate.

7. The method according to claim 1, in which the components (a) and (b) are administered in the ratio (a):(b) of 1:1 to 1:500.

8. The method according to claim 1, in which the components (a) and (b) are administered simultaneously or sequentially.

9. The method of claim 1, wherein glaucoma is treated.

10. A pharmaceutical composition for treatment of ocular hypertension by ocular administration thereof comprising an oculo-hypotensively synergistic combination of

(a) a 13,14-dihydro-15-keto-20-loweralkylprostaglandin or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof, and

(b) a polyoxyethylenesorbitan unsaturated higher aliphatic acid monoester in association with a pharmaceutically acceptable carrier, diluent or excipient.

11. The pharmaceutical composition according to claim 10, in which the component (a) is a 13,14-dihydro-15-keto-20-ethylprostaglandin F2.alpha., or a pharmaceutically acceptable salt thereof, or a lower alkyl ester thereof, and the component (b) is a polyoxyethylenesorbitan monooleate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Mallinckrodt
Daiichi Sankyo
Covington
US Army
QuintilesIMS
AstraZeneca
Citi
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot